American Diabetes Association Announces New Awards for Research in Cardiovascular Disease Among People with Diabetes
February 15, 2017
Three recipients will receive up to $150,000 over two years, supported by Pfizer Inc.
The American Diabetes Association (Association) today announced a new funding opportunity to support research into cardiovascular disease (CVD) among people with diabetes, one of the most dangerous and deadly complications of the disease. The American Diabetes Association New England Cardiovascular-Metabolic Fellowship Awards, supported by Pfizer Inc., will provide three fellowship recipients with $150,000 over two years for studies focused on improving our understanding of the pathophysiology, treatment and prevention of CVD in people with diabetes.
"People with diabetes are 1.7 times more likely to die from cardiovascular disease than people without diabetes, and while we have tools and treatments available, increasing our knowledge about the intersection of diabetes and cardiovascular disease is critical to achieving better outcomes," said Tamara Darsow, PhD, interim chief scientific & medical officer, American Diabetes Association and vice president, research programs and outcomes research. "The Association is thrilled to be able to facilitate research with the potential to unlock new information and improve the lives of individuals with diabetes."
The funding opportunity will support research in the areas of fundamental biology, mechanistic and outcome-based clinical studies, behavioral research and epidemiologic research in a broad scope of areas including:
- Mechanistic studies to examine the pathophysiology of cardiovascular disease in the context of diabetes;
- Clinical investigations aimed at defining the optimal therapeutic approaches for addressing cardiovascular risk factors in people with diabetes;
- Strategies for improved care delivery for patients with diabetes and CVD, including the development of improved clinical decision support tools; and
- Studies examining the effect of treatment approaches on the progression of cardiovascular disease in people with diabetes.
"We're proud to support the American Diabetes Association's New England Cardiovascular-Metabolic Fellowship Awards as another sign of our enduring commitment to ease the burden of metabolic disease and its cardiovascular complications for people with diabetes," said Morris Birnbaum, MD, PhD, senior vice president and chief scientific officer for the Internal Medicine Research Unit, from Pfizer Inc. "Despite the progress made, cardiovascular complications remain the number one cause of death in people with diabetes. We enthusiastically support the Association in its goal of encouraging a new generation of investigators to focus their efforts on finding new and better ways to manage and ultimately prevent cardiovascular disease in people with diabetes."
Applications from postdoctoral fellows for support of basic, clinical or translational research focused on cardiovascular disease in the context of diabetes will be considered. Fellows supported with this award must perform their fellowship training in the New England region (Massachusetts, Maine, Rhode Island, New Hampshire, Vermont and Connecticut). Applications must be submitted by April 17, 2017. Complete information, including instructions and budget forms are available at diabetes.org/grants.
The Association has a rigorous peer review process that is employed to evaluate grants for funding across all of its research programs. For this initiative, the Association will convene an expert review committee to include experts in diabetes, metabolism, endocrinology, atherosclerosis and cardiovascular disease. Each research program application will be independently reviewed and scored by this committee.
About the American Diabetes Association
Nearly half of American adults have diabetes or prediabetes; more than 30 million adults and children have diabetes; and every 21 seconds, another individual is diagnosed with diabetes in the U.S. Founded in 1940, the American Diabetes Association (ADA) is the nation’s leading voluntary health organization whose mission is to prevent and cure diabetes, and to improve the lives of all people affected by diabetes. The ADA drives discovery by funding research to treat, manage and prevent all types of diabetes, as well as to search for cures; raises voice to the urgency of the diabetes epidemic; and works to safeguard policies and programs that protect people with diabetes. In addition, the ADA supports people living with diabetes, those at risk of developing diabetes, and the health care professionals who serve them through information and programs that can improve health outcomes and quality of life. For more information, please call the ADA at 1-800-DIABETES (1-800-342-2383) or visit diabetes.org. Information from both of these sources is available in English and Spanish. Find us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn)